JP2005515237A5 - - Google Patents

Download PDF

Info

Publication number
JP2005515237A5
JP2005515237A5 JP2003561504A JP2003561504A JP2005515237A5 JP 2005515237 A5 JP2005515237 A5 JP 2005515237A5 JP 2003561504 A JP2003561504 A JP 2003561504A JP 2003561504 A JP2003561504 A JP 2003561504A JP 2005515237 A5 JP2005515237 A5 JP 2005515237A5
Authority
JP
Japan
Prior art keywords
type
igg antibody
antibody concentration
weeks
sufficient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003561504A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005515237A (ja
Filing date
Publication date
Priority claimed from US09/955,585 external-priority patent/US20030113350A1/en
Application filed filed Critical
Publication of JP2005515237A publication Critical patent/JP2005515237A/ja
Publication of JP2005515237A5 publication Critical patent/JP2005515237A5/ja
Pending legal-status Critical Current

Links

JP2003561504A 2001-09-19 2002-09-19 免疫無防備状態の個体群に用いる糖コンジュゲートワクチン Pending JP2005515237A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/955,585 US20030113350A1 (en) 2001-09-19 2001-09-19 Glycoconjugate vaccines for use in immune-compromised populations
PCT/US2002/029601 WO2003061558A2 (en) 2001-09-19 2002-09-19 Glycoconjugate vaccines for use in immune-compromised populations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010155473A Division JP2010265293A (ja) 2001-09-19 2010-07-08 免疫無防備状態の個体群に用いる糖コンジュゲートワクチン

Publications (2)

Publication Number Publication Date
JP2005515237A JP2005515237A (ja) 2005-05-26
JP2005515237A5 true JP2005515237A5 (https=) 2006-01-12

Family

ID=25497036

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003561504A Pending JP2005515237A (ja) 2001-09-19 2002-09-19 免疫無防備状態の個体群に用いる糖コンジュゲートワクチン
JP2010155473A Pending JP2010265293A (ja) 2001-09-19 2010-07-08 免疫無防備状態の個体群に用いる糖コンジュゲートワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010155473A Pending JP2010265293A (ja) 2001-09-19 2010-07-08 免疫無防備状態の個体群に用いる糖コンジュゲートワクチン

Country Status (11)

Country Link
US (2) US20030113350A1 (https=)
EP (1) EP1427442A4 (https=)
JP (2) JP2005515237A (https=)
KR (3) KR101214766B1 (https=)
CN (1) CN1306958C (https=)
CA (1) CA2460749C (https=)
EA (1) EA006602B1 (https=)
MX (1) MXPA04002624A (https=)
NZ (1) NZ548453A (https=)
WO (1) WO2003061558A2 (https=)
ZA (1) ZA200402185B (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100217772B1 (ko) * 1996-09-03 1999-09-01 최진호 조명기기의 램프 과열방지 장치 및 방법
US20020092987A1 (en) * 1998-09-05 2002-07-18 Taehee Cho Photo detect device using quantum dots and materialization method thereof
US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
WO2004043405A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
EP1567868A4 (en) * 2002-12-02 2008-02-06 Biosynexus Inc CELL WALL TEICHONSURE AS A GOAL F RANTI-STAPHYLOCOCCUS THERAPIES AND VACCINATES
BRPI0408167B1 (pt) 2003-03-07 2014-10-21 Wyeth Corp Conjugados de polissacarídeo-proteína veículo adesina da superfície estafilocócica para imunização contra infecções nosocomiais
AU2011265368B9 (en) * 2004-09-22 2012-11-29 Biosynexus Incorporated Immunogenic composition
KR20070058631A (ko) * 2004-09-22 2007-06-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
EP1850867A1 (en) * 2005-01-10 2007-11-07 Nabi Biopharmaceuticals Method of treating staphylococcus aureus infection
US20060228368A1 (en) * 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
FR2884830A1 (fr) 2005-04-25 2006-10-27 Sanofi Pasteur Sa Procede de production de souches de staphylococcus aureus surproductrices
AU2006275865B2 (en) * 2005-07-29 2012-06-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Mutated Pseudomonas exotoxins with reduced antigenicity
MY148405A (en) * 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
FR2899110A1 (fr) 2006-03-31 2007-10-05 Sanofi Pasteur Sa Polysaccharides capsulaires de type 5 et de type 8 des souches surproductrices de staphylococcus aureus
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
EP2185190B1 (en) * 2007-08-31 2015-06-24 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
KR20110031393A (ko) * 2008-07-21 2011-03-25 더 브리검 앤드 우먼즈 하스피털, 인크. 합성 베타-1,6 글루코사민 올리고당에 관한 방법 및 조성물
WO2010014304A1 (en) * 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
ES2784957T3 (es) 2009-04-03 2020-10-02 Univ Chicago Composiciones y métodos relacionados con variantes de la proteína A (SPA)
HUE036372T2 (hu) 2009-06-22 2018-07-30 Wyeth Llc Staphylococcus aureus antigének immunogén készítményei
BRPI1011753B8 (pt) 2009-06-22 2021-05-25 Wyeth Llc conjugados imunogênicos de polissacarídeo capsular de staphylococcus aureus de sorotipos 5 e 8, seu uso e composições que os compreendem
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
US8974799B2 (en) 2009-09-30 2015-03-10 Novartis Ag Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
BR112012010223A2 (pt) * 2009-10-30 2016-12-06 Novartis Ag purificação de staphylococcus aureus tipo 5 e tipo 8 sacarídeos capsulares
WO2011088843A1 (en) * 2010-01-19 2011-07-28 Universitätsklinikum Freiburg Enterococcal cell wall components and antibacterial use thereof
JP6002128B2 (ja) 2010-07-02 2016-10-05 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ プロテインＡ（ＳｐＡ）変種に関連する組成物および方法
CN102565336A (zh) * 2010-12-13 2012-07-11 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102539726A (zh) * 2010-12-13 2012-07-04 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102565354A (zh) * 2010-12-13 2012-07-11 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102539708A (zh) * 2010-12-13 2012-07-04 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102565332A (zh) * 2010-12-13 2012-07-11 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102539704A (zh) * 2010-12-13 2012-07-04 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102539702A (zh) * 2010-12-13 2012-07-04 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
EP2872535A1 (en) * 2012-07-16 2015-05-20 Pfizer Inc. Saccharides and uses thereof
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
AU2015359503B2 (en) 2014-12-10 2019-05-09 Glaxosmithkline Biologicals Sa Method of treatment
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
WO2020163512A1 (en) 2019-02-05 2020-08-13 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
MX2021013833A (es) 2019-05-14 2022-03-17 Univ Chicago Metodos y composiciones que comprenden variantes de la proteina a de estafilococos (spa).
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
WO2021041721A1 (en) * 2019-08-27 2021-03-04 OneBioPharma, Inc. Antimicrobial vaccine compositions
WO2021051136A1 (en) 2019-09-13 2021-03-18 The University Of Chicago Methods and compositions for treating staphylococcal infections
US20260007731A1 (en) * 2022-01-05 2026-01-08 Bluewillow Biologics, Inc. Intranasal polysaccharide conjugate nanomulsion vaccines and methods of using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747024A (en) * 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
US5770208A (en) * 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen

Similar Documents

Publication Publication Date Title
JP2005515237A5 (https=)
Jones et al. Does atopic disease start in foetal life?
DE60304993D1 (de) In der mundhöhle dispergierbare pharmazeutische zusammensetzung mit agomelatin
JP2007509067A5 (https=)
FR2847307B1 (fr) Collecteur d'admission en deux parties
AU2003304343A1 (en) Antigen epitopes of the regulatory protein of virulence factor in staphylococcus aureus and their mimotopes and use
Center BOXING
de Greeff et al. First effects of meningococcal C vaccination campaign in the Netherlands
WO2004035003A3 (en) Therapeutic adjuvant
TRIMBLE Beijing Parks [Part 3]
CN2503796Y (zh) 带镜框花瓶
DE60305642D1 (de) In der mundhöhle dispergierbare pharmazeutische zusammensetzung mit piribedil
FR2838639B1 (fr) Sucette detectant l'etat febrile chez l'enfant
ZHIGUO Holy Lakes in Snowland
JP2003116920A5 (https=)
潘世豪 A Happy Day
刘剑锋 Keeping Pace With the New Century
孙忠海 Spring Festival
Mullins Simply fishing
王国峰 Thank You” and “Excuse me
Pearson Response to Jesus in Beijing by David Aikman
TH29400S1 (th) เก้าอี้
TH29402S1 (th) "เก้าอี้"
TH29405S1 (th) "เก้าอี้"
TH92331S (th) "เก้าอี้"